672 related articles for article (PubMed ID: 25703568)
1. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
2. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
3. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
[TBL] [Abstract][Full Text] [Related]
6. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
Hawn TR; Shah JA; Kalman D
Immunol Rev; 2015 Mar; 264(1):344-62. PubMed ID: 25703571
[TBL] [Abstract][Full Text] [Related]
7. Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility.
Raffetseder J; Pienaar E; Blomgran R; Eklund D; Patcha Brodin V; Andersson H; Welin A; Lerm M
PLoS One; 2014; 9(11):e112426. PubMed ID: 25386849
[TBL] [Abstract][Full Text] [Related]
8.
Petruccioli E; Petrone L; Chiacchio T; Farroni C; Cuzzi G; Navarra A; Vanini V; Massafra U; Lo Pizzo M; Guggino G; Caccamo N; Cantini F; Palmieri F; Goletti D
Front Immunol; 2021; 12():716857. PubMed ID: 34447382
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
Lenaerts A; Barry CE; Dartois V
Immunol Rev; 2015 Mar; 264(1):288-307. PubMed ID: 25703567
[TBL] [Abstract][Full Text] [Related]
11. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
13. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
14. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
15. Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.
Sikri K; Duggal P; Kumar C; Batra SD; Vashist A; Bhaskar A; Tripathi K; Sethi T; Singh A; Tyagi JS
Redox Biol; 2018 May; 15():452-466. PubMed ID: 29413958
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the global crisis: "yes, we can", but also for TB ... ?
Ottenhoff TH
Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
18. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
Lin MY; Ottenhoff TH
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
[TBL] [Abstract][Full Text] [Related]
19. Targeting redox heterogeneity to counteract drug tolerance in replicating
Mishra R; Kohli S; Malhotra N; Bandyopadhyay P; Mehta M; Munshi M; Adiga V; Ahuja VK; Shandil RK; Rajmani RS; Seshasayee ASN; Singh A
Sci Transl Med; 2019 Nov; 11(518):. PubMed ID: 31723039
[TBL] [Abstract][Full Text] [Related]
20. Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum.
Walter ND; Moore CM; Kayigire XA; Dide-Agossou C; Worodria W; Huang L; Everett CK; Schoolnik GS; Nahid P; Davis JL
BMC Infect Dis; 2018 Jul; 18(1):293. PubMed ID: 29970012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
